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A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate
toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance
status o3, caloric intake 41500kcalday
 1 were included. Chemotherapy, with cisplatin 30mgm
 2 and irinotecan 60mgm
 2, was
administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50
or 50.4Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years
(range 44–79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe
toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31
severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred
(diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4–72.8%). Overall survival rate at 1 and 2 years was
62.8%, (95% CI, 58.3–77.3%) and 27.9% (95% CI, 13.4–41.3%), respectively. In conclusion, cisplatin–irinotecan–radiotherapy is an
active and well-tolerated regimen feasible in out-patients.
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Oesophageal cancer is an aggressive disease with a poor prognosis
(Enzinger and Mayer, 2003). In the USA and Europe the number
of new cases per year is 13100 and 34300, respectively (Jemal
et al, 2002; Keighley, 2003). At the time of the diagnosis, more
than 50% of patients have inoperable disease. In these patients,
the more effective treatment in locally advanced disease is
chemo-radiotherapy (Enzinger and Mayer, 2003). Moreover, in
operable patients with locally advanced oesophageal cancer, the
combination of chemotherapy and concurrent radiotherapy has
been demonstrated to have an outcome similar to that of surgery
after preoperative therapy (Bedenne et al, 2002; Stahl et al, 2005).
The standard chemotherapy regimen associates 5 Fluorouracil
(FU) with cisplatin (Herskovic et al, 1992; Cooper et al, 1999)
and the recommended total dose of concurrent radiation is 50Gy
(Minsky et al, 2002). A number of drugs have been tested in
oesophageal cancer (Enzinger et al, 1999; Geh, 2002). Recent
trials combining weekly irinotecan with cisplatin have reported a
response rate exceeding 50% (Ilson et al, 1999; Ajani et al,
2002). The active metabolite of irinotecan (SN38) increases the
proportion of cells in the G2–M or M phase. These phases are the
most radiosensitive of the cycle (Tamura et al, 1997). Phase I–II
studies of weekly irinotecan and radiation therapy have been
performed (Koukourakis et al, 1999; Takeda et al, 1999).
Recently, phase I study of weekly with cisplatin–irinotecan
chemotherapy followed by chemo-radiotherapy in locally
advanced oesophageal cancer has been reported (Ilson et al,
2003). The dose-limiting toxicity was primarily myelosuppression,
no grade 3 or 4 oesophagitis, diarrhoea or stomatitis was
observed.
In the current multicentre phase II trial, our aim was to evaluate
the efficacy and toxicity of cisplatin–irinotecan chemotherapy
followed with chemo-radiotherapy as definitive treatment in
patients with oesophageal cancer. Received 24 May 2006; revised 24 July 2006; accepted 25 July 2006
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sPATIENTS AND METHODS
Patient eligibility
All patients had histologically confirmed squamous cell carcinoma,
adenocarcinoma or poorly differentiated non-small-cell carcinoma
of the oesophagus. Participants were required to be at least 18
years of age and to provide written informed consent prior to
treatment. Patients had an Eastern Cooperative Oncology Group
(ecog) performance status p2 (Karnofsky performance status of
70% or greater), caloric intake 41500kcald
 1, serum albumin
X32gl
 1 and adequate haematological, renal, and hepatic
function as defined by an absolute neutrophil count
X1.5 10
9l
 1, platelets X100 10
9l
 1, serum creatinine
p120mmoll
 1 and total serum bilirubin p1.5mgdl
 1. Patients
had no prior chemotherapy, radiotherapy or surgery. Patients with
metastatic disease to supraclavicular or metastatic disease with
biopsy-proven tumour invasion of the tracheobronchial tree or
with tracheoesophageal fistula were not included. Patients with
severe comorbid conditions, including cardiac disease graded as
New York Heart Association class 3 or 4, or myocardial infarction
within the previous 6 months were also excluded. Also patients
with a prior history of malignancy, other than basal cell carcinoma
of the skin, in situ cervical carcinoma, or head and neck carcinoma
with complete response since 3 years of inclusion of the study were
also not included. Patients with known Gilbert’s syndrome were
not included.
Pretreatment evaluation and evaluation on study
Pretreatment evaluation included a detailed medical history and
physical examination, a complete blood count, biochemical
screening profile including liver function assessment and electro-
lytes, a prothrombin time and ECG. Radiologic evaluation included
a CT scan of the chest and abdomen. Patients were required to
undergo endoscopy with biopsy of the primary tumour. Endo-
scopy with ultrasonography (EUS) was optional. Bronchoscopy
was performed in patients with tumours of the cervical or proximal
thoracic oesophagus and in patients with squamous cell carcino-
ma. The 1983 AJCC staging system (Table 1) was used in this study
according to published recommendations (Coia et al, 2000).
Patients were examined the morning prior to each chemotherapy
infusion during induction chemotherapy and combined chemo-
radiotherapy. At 10–12 weeks after completion of therapy, an
upper endoscopy with biopsy, and a CT scan were repeated to
assess response. Clinical complete response was defined as no
tumour detectable on oesophagus endoscopy and no appearance of
lymph nodes or distant metastasis on CT scan (Kelsen et al, 1983;
Jones et al, 1999). In all other cases, the patients were considered in
the absence of response. Surgery was not mandated on protocol.
When patients achieved a complete clinical response, immediate
follow-up was carriedout at the discretion of the investigator.
Upper endoscopy and CT scan of the chest and abdomen were
performed annually. Dysphagia was evaluated prior to therapy and
after completion of induction chemotherapy using a previously
published dysphagia scale (Ogilvie et al, 1982). All toxicity was
graded using the National Cancer Institute Common Toxicity
Criteria version 2.0.
Treatment plan
The treatment procedure is outlined in Figure 1. Therapy was
delivered in two phases: four induction chemotherapy courses
were administered on days 1, 8, 22, 29 with the third and sixth
week used as rest weeks. Four chemotherapy courses concurrent
with radiotherapy (courses 5 to 8) were administered days 43, 50,
64 and 71 with the ninth week used as a rest week. Antiemetic
therapy, with steroid and 5-HT3 receptor antagonist was
recommended. Hydration with 500ml of intravenous fluid was
performed before cisplatin at a dose of 30mgm
 2 as a 30-min
infusion. After cisplatin, irinotecan was administered at a dose of
60mgm
 2 as a 30-min infusion. As required, atropine 0.5mg was
given to patients who developed abdominal cramps or diarrhoea
within 1h of irinotecan infusion. Written information regarding
the treatment of diarrhoea as delayed toxicity was routinely given
at the first chemotherapy. All diarrhoeas were treated by
loperamide. To continue induction chemotherapy, patients were
required to maintain a WBC X3.0 10
9l
 1, absolute neutrophil
count X1.5 10
9l
 1, platelet count X100 10
9l
 1, serum creati-
nine p120mgl
 1 and diarrhoea toxicity pgrade 2. No prophylac-
tic use of granulocyte colony-stimulating factor was planned.
Radiation therapy
Radiation therapy was delivered with megavoltage equipment
using a multiple-field technique. Patients were treated 5 days per
week at 1.8 or 2Gyday
 1 to a total dose of 50.4 or 50.0Gy. All
fields were treated each day. Treatment was delivered to three or
four fields (anterior–posterior/posterior–anterior and opposed
laterals) in order that the dose did not vary by more than 5% over
the entire target volume. The prescribed total dose was prescribed
at the reference point (isocentre) of the PTV, which covered the
volume at risk. The upper and lower borders of the radiation field
were 3–5cm beyond the primary tumour. The lateral, anterior and
posterior borders of the field were X2cm beyond the borders of
the primary tumour. The tumour size was defined by CT scan. The
primary and regional lymph nodes were also included.
Table 1 The 1983 AJCC staging system for oesophageal cancer
Stage Criterion
I o5cm in length, nonobstructing, noncircumferential
II 4 5cm in length or obstructing or circumferential
III Evidence of extra oesophageal spread (computed tomography
scan indicating invasion of surrounding structures or clinical evidence
such, as recurrent laryngeal nerve involvement, positive pleural effusion,
tracheoesophageal fistula, sympathetic nerve involvement, phrenic nerve
involvement or widened mediastinum on chest radiograph)
Cisplatin 30 mg m−2  
Irinotecan 60 mg m−2 
Radiotherapy, 50.4 Gy, 1.8 Gy day−1  
D1 D8 D22 D29 D43 D50 D64 D71
Figure 1 Treatment flow chart.
Chemoradiotherapy alone in oesophageal cancer
P Michel et al
706
British Journal of Cancer (2006) 95(6), 705–709 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sStatistical design
The primary end point of the study was clinical complete response
rate. The study was designed using a two-stage design (Bellisant
et al, 1996). Assuming clinical complete response rate at 60% with
alpha risk 5% and power 80%, the number of patients necessary
was calculated at 43. In the first stage, 34 patients were accrued. If
clinical complete response was observed in less than 17 patients,
the trial was considered closed due to ineffectiveness of studied
regimen. If more than 17 patients presented a complete clinical
response, inclusion was continued to 43 patients. Analysis was
performed in intent to treat. Quantitative data were presented as
mean or median. Qualitative data were presented with frequency
and percentage. The proportion of patients with clinical complete
response was used to estimate the true response rate with a 95%
confidence interval (95% CI). Overall survival and survival without
recurrence rate at 1 and 2 years was estimated. The dysphagia scale
used had five stages (Ogilvie et al, 1982). For results analysis
patients were pooled in two groups (1–2, 42). Dysphagia prior to
and after induction chemotherapy was compared. Then, relation-
ship between dysphagia after induction chemotherapy and
response was evaluated. These groups were compared using the
Wilcoxon–Mann–Whitney test.
RESULTS
Between February 2003 and December 2003, 43 patients were
included. Patient characteristics are listed in Table 2. Histological
type was squamous cell carcinoma in 38 out of 43 patients (88.4%).
At the inclusion, 12 out of 43 patients (27.9%) presented a severe
weight loss (415%) and 26 out of 43 patients (60.5%), a moderate
deterioration of performance status (ECOG 1).
Treatment
Of the 43 patients included, 30 (69.8%) completed treatment as
planned, 35 patients (81.4%) completed the four cycles of
induction chemotherapy and 34 patients (79.1%) completed the
total doses of radiation therapy. Radiotherapy with 2Gy per
fraction was performed in 31 patients (79.5%). In eight patients, a
radiotherapy protocol violation recorded with fractions number
superior to 25. The total dose was 56Gy in 1, 60Gy in 4, 62Gy in 1
and 64Gy in 1. In eight patients (18.6%) treatment was stopped
due to toxicity (4 haematological, 4 nonhaematological). In four
patients, treatment was stopped after cycle 7 due to nonadherence
to protocol without toxic effect reported. One patient declined to
undergo the last cycle of induction chemotherapy. During
induction chemotherapy period, dose attenuation was required
in less than 10% of patients: course 3 (cisplatin 1 patient,
irinotecan 4 patients); course 4 (irinotecan 2 patients). Treatment
delay occurred in 15 and 5.7% of patients, respectively, at course 3
and 4. The delay was due to haematological toxicity in 87.5% of
cases. During chemo-radiotherapy period, dose attenuation was
performed at courses 5, 6, 7 and 8, in 22.1, 23.0, 25.7 and 24.3% of
patients for cisplatin and in 22.1, 28.6, 28.6 and 30.3% of patients
for irinotecan, respectively. Treatment delay occurred in 21.0, 20.0,
20.0 and 15.6% of patients, respectively, at courses 5, 6, 7 and 8.
Treatment delay was due to haematological toxicity in 24 out of 27
(88.9%) of cases, the other causes were dysphagia (2 patients) and
deep thrombosis (one patient). The most common cause of dose
attenuation was haematologic toxicity.
Toxicity
Toxicities observed during induction chemotherapy are listed in
Table 3. During this period, 246 toxicities were reported with
56.9% due to haematoxcicity. Fourteen severe toxicities of grade 3
or 4 in 10 patients (23.3%) were reported with 57.1% due to
haematoxcicity. Hospitalisation was required in five patients
during this period, due to deficient nutritional intake (two
patients), myocardial infarction (one patient), severe diarrhoea
(grade 4) (one patient) and tracheoesophageal fistula (one patient).
Toxicities observed during chemoradiotherapy are listed in
Table 4. During this period, 311 toxicities were reported with
72.8% due to haematotoxicity. Thirty-one severe toxicities of grade
3 or 4 with 64.5% due to haematotoxicity were reported in 18
patients. During this period, no grade 3–4 alopecia was recorded.
Only one deep thrombosis was observed. The other non-
Table 2 Patient characteristics
N¼43
Age in years (mean) 59.2yrs (60.9yrs)
Sex ratio 30 males/4 females
Histology n (%)
Squamous cell carcinoma 38 (88.4%)
Adenocarcinoma 4 (9.3%)
Poor differenced 1 (2.3%)
Tumour n (%)
Proximal 15 (34.9%)
Middle 19 (44.2%)
Distal 9 (20.9%)
Dysphagia (Atkinson score ): n (%)
Grade42 12 (29.3%)
Performance status ECOG: n (%)
0 17 (39.5%)
1–2 26 (60.5%)
Weight loss n (%)
o15% 31 (72.1%)
415% 12 (27.9%)
Tumour stage, UICC 1983: n (%)
Stage I 10 (23.2%)
Stage II 19 (44.2%)
Stage III 14 (32.6%)
Serum albumin (mean in gl
 1) 39.5gl
 1
Tumour diameter (CT scan, median in mm) 34.5mm
Endoscopic Ultrasonography (n¼12)
T3 9 (75%)
N+ 6 (50%)
M1a (celiac node) 1 (8.3%)
Table 3 Toxicity episodes: induction chemotherapy
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia 9 9 0 0
Anaemia 75 13 0 0
Diarrhoea 26 3 1 1
Fever 1 1 0 0
Infection+neutropenia 0 1 0 0
Nausea-vomiting 32 13 1 0
Neutropenia 22 11 6 1
Febrile neutropenia 0 4 0 0
Mucositis 6 0 0 0
Thrombopenia 5 1 1 0
Deep thrombosis 0 0 0 0
Heart 0 0 0 1
Fatigue 0 0 0 1
Esotracheal fistula — — — 1
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shaematological toxicities were tachycardia (one), and common
toxicities with chemotherapy (functional kidney failure: one,
mucositis: one) and radiotherapy (dysphagia: two, asthenia: four).
Seventeen hospitalisations in 13 patients were required. Hospita-
lisations were required for vomiting, dysphagia or oesophagitis
(six), only biological disorders (seven), sepsis (one), asthenia (one)
and deep thrombosis (one). One treatment-related death occurred:
4 days after the cycle 7, patient 31 presented with a severe
diarrhoea grade 4 with vomiting. This patient was hospitalised in
the emergency ward. He developed aplasia and kidney failure, and
later died from septic shock.
Severe adverse events were reported in 24 patients (55.8%)
during the treatment; 11 (25.6%) and 13 (30.2%) of patients during
induction chemotherapy and chemo-radiotherapy, respectively.
Response and survival
Twenty-five of 43 included patients (58.1%; 95% CI, 43.4–72.8%)
achieved a complete clinical response. In 14 patients, the complete
clinical response was defined by endoscopy with biopsy, in other
patients only macroscopic characteristics were used. Thirteen
patients (30.2%; 95% CI, 16.5–43.9%) were in the absence of
response as previously defined (i.e. partial response, stable disease
or progression). Five patients were not available for response, as
four patients discontinued treatment prior to radiotherapy and
one patient died before evaluation. One patient was lost to follow-
up after the first cycle of chemotherapy, the 42 other patients were
followed-up at 2 years or to death. Overall survival rate at 1 and 2
years were 62.8% (95% CI, 58.3–77.3%) and 27.9% (95% CI, 13.4–
41.3%), respectively. The disease free survival rate at 1 and 2 years
was 23.2% (95% CI, 10.6–35.8%) and 16.7% (95% CI, 5.6–27.8%).
Three patients underwent surgery during follow-up period for
suspected local recurrence. In one case (i.e. poor differentiated
tumour) oesophageal EUS performed 2 months after the treatment
suggested a stable disease (uT3) when endoscopy was normal. The
pathologic examination of the surgical specimen showed the
absence of cancer cells and confirmed the clinical complete
response. In the two other cases, local recurrence was confirmed
by biopsies, in one patient the tumour was not resectable.
Dysphagia
Only 12 patients (29.3%) had dysphagia (grade42) prior to the
treatment. After induction chemotherapy and chemo-radio-
therapy, 15 (38.5%) and 6 (17.1%) patients, respectively,
experienced dysphagia (grade42). The differences were not
statistically significant with P¼0.565 and 0.099, respectively
(Table 5). No significant correlation was found between dysphagia
after induction chemotherapy and clinical response after the
treatment (P¼0.797). The variation of weight during the treatment
regimen was mean  0.3kg (range: þ2t o 13kg).
DISCUSSION
The present study is to our knowledge the first phase II trial
evaluating in a population of inoperable patients with the regimen
defined in phase I (Ilson et al, 2003). The main results of the
present study were the complete clinical response rate of 58.1%
(95% CI, 43.4–72.8%), overall survival rate of 27.9% (95% CI:
13.4–41.3%) at 2 years and the absence of significant improvement
of dysphagia after induction chemotherapy. Compliance was
satisfactory in 69.8% patients who completed treatment as planned
although a severe adverse event was reported in 24 patients
(55.8%).
The combination of weekly cisplatin–irinotecan in metastatic
oesophageal cancer showed an objective response rate of 57%
(Ilson et al, 1999). In the present study, the clinical complete
response rate obtained with cisplatin–irinotecan and radiotherapy
regimen was 58.1% (CI 95%: 43.4–72.8%), in a range similar to
that reported with a FU–cisplatin and radiotherapy regimen (Seitz
et al, 1990; Poplin et al, 1996; Geh, 2002). The overall survival rate
at 2 years of 27.9% (CI 95%: 13.4–41.3%) in our study was similar
to the result of standard treatment of definitive concomitant
reported in the RTOG-8501 trial and the recent phase III study
with chemo-radiotherapy as definitive treatment (Herskovic et al,
1992; Bedenne et al, 2002; Minsky et al, 2002; Stahl et al, 2005). All
results published with cisplatin–irinotecan regimen suggest that
its efficacy is similar to that of a standard regimen with FU–
cisplatin for response rate and overall survival (Geh, 2002).
In the present study, no significant improvement of dysphagia
was obtained by induction chemotherapy. However, in other
studies using this combination of irinotecan–cisplatin in che-
motherapy, a significant improvement of dysphagia was reported
(Ilson et al, 1999; Tew et al, 2005). Ilson et al observed dysphagia
resolution in 70% of patients after four chemotherapy courses. In
our study, only 28.1% of patients reported dysphagia resolution
after induction chemotherapy.
The development of regimens with induction chemotherapy has
been significant; therefore, this regimen should have a similar
efficacy as compared to the standard regimen. In contrast, the
optimisation of the cisplatin–irinotecan–radiotherapy regimen
could be potentially feasible. Epidermal growth factor receptor
(EGFr) antibody or inhibitor could also increase the efficacy of the
regimen: first by improving the therapeutic effect of irinotecan via
EGFr antibodies as demonstrated in vitro (Prewett et al, 2002),
second by the specific approach as demonstrated in head and neck
cancer, by using radiation therapy and EGF receptor antibodies
(Bonner et al, 2006; Pfister et al, 2006). The association cisplatin–
irinotecan–radiotherapy with EGFr antibody warrants further
study.
Table 4 Toxicity episodes: combined chemoradiotherapy
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia 13 7 0 0
Anaemia 97 36 5 0
Diarrhoea 11 3 0 0
Fever 3 0 0 0
Oesophagitis
a 21 17 5 1
Infection+neutropenia 0 0 0 1
Nausea-vomiting 27 0 0 0
Leuconeutropenia 31 11 9 3
Neutropenia and fever 1 16 0 1
Mucositis 9 0 1 0
Thrombopenia 13 2 2 0
Deep thrombosis 0 0 1 0
Heart 0 0 1 0
Sepsis 0 0 0 1
Kidney 0 0 1 0
Asthenia 0 0 4 0
aOesophagitis defined by painful dysphagia and/or thoracic burning.
Table 5 Dysphagia
Atkinson
score
Before
treatment
N¼41
End of induction
chemotherapy
N¼39
End of
chemoradiotherapy
N¼35
1 4 11 16
22 5 1 3 1 3
38 8 2
44 6 3
50 1 1
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sIn the present study, planned treatment was performed in 69.8%
of patients. This compliance is similar to 68% observed with 5FU
and cisplatin in the RTOG 85-01 trial (Herskovic et al, 1992;
Cooper et al, 1999). A severe adverse event was observed in 44
and 55.8% of patients in the RTOG 85-01 study and our
phase II, respectively. In the present study, two patients (4.6%)
presented life-threatening events compared with 20% in RTOG
study. Haematotoxicity represented 62.2% of severe adverse
events as in other regimens evaluated in patients with oesophageal
cancer (Geh, 2002). In RTOG 85-01 trial, grade 3–4 esophagitis
occurred in 33% of patients receiving chemo-radiotherapy
(Herskovic et al, 1992). In present study only three patients (7%)
reported a grade 3–4 oesophageal toxicity. The incidence of
clinical deep thrombosis was poor with only one case reported in
our study.
In conclusion, cisplatin–irinotecan–radiotherapy regimen
could be considered effective and its tolerance is similar to the
standard treatment. Moreover, the regimen can be performed on
an outpatient basis. Furthermore, chemotherapy induction and the
possibility to optimise the association with EGFr antibody
warrants further studies with the combination irinotecan–
cisplatin and radiotherapy in patients with oesophageal cancer.
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